LOS ANGELES—Direct infusions of human HDL — to speedily boost HDL levels —could be an answer to preventing re-infarction in patients who’ve just had a heart attack and are at high risk of having another, according to conclusions from a phase I study released at the 2012 American Heart Association annual sessions in Los Angeles. Sarah Maxwell heard from Andreas Gille, Head of Clinical and Translational Science Strategy at the company CSL Ltd in Melbourne, Australia, about their findings from healthy volunteers receiving CSL 112 — a form of human apo-lipoprotein A1 purified from human plasma and reconstituted with phospholipid to yield HDL particles suitable for I/V infusion.
LISTEN
[audio:https://www.audiomedica.com/podcasting/aha/121115AndreasGillePODCASTLoRes.mp3]
